Erbitux Drug Fails In Colon Cancer Study That May Limit Its Use
BRIEF: Erbitux Drug Fails In Colon Cancer Study That May limit its use [The Indianapolis Star]
From Indianapolis Star (IN) (October 11, 2010)
Oct. 11--Eli Lilly & Co. and Merck KGaA’s Erbitux failed to help colon cancer patients in a study, which may leave doctors less likely to combine the drug with a certain type of chemotherapy, according to a Bloomberg report.
Erbitux didn’t slow or delay the progression of tumors and didn’t prolong patients’ lives, according to a study released Sunday at the European Society for Medical Oncology conference in Milan. Patients with a normal version of a gene called KRAS didn’t respond better than those with a mutation.
The results add to a growing body of evidence that Erbitux, known chemically as cetuximab, might not work in certain chemotherapy combinations, said Kjell Magne Tveit, an oncologist at Oslo University Hospital and a researcher on the study. The drug didn’t keep colon cancer at bay in a United Kingdom trial last year. That trial combined Erbitux with oxaliplatin, the same chemotherapy as in the study presented Sunday.
To see more of The Indianapolis Star or to subscribe to the newspaper, go to http://www.indystar.com/.
Copyright (c) 2010, The Indianapolis Star
Distributed by McClatchy-Tribune Information Services.
For more information about the content services offered by McClatchy-Tribune Information Services (MCT), visit www.mctinfoservices.com, e-mail email@example.com, or call 866-280-5210 (outside the United States, call +1 312-222-4544)
Posted: October 2010